Compound Evidence File
#EC-2026-0570
Humanin
Filed under Peptides. The bureau holds 146 laboratory returns for this compound from 55 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
55 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 5 | 10.0 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 10.0 | 9.9 | 10.0 | 26 Apr 2026 | 20 Jun 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 4 | 10.0 | 9.9 | 10.0 | 13 Jun 2026 | 28 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 10.0 | 9.9 | 10.0 | 11 Apr 2026 | 26 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 3 | 10.0 | 9.9 | 10.0 | 7 Feb 2026 | 3 Jun 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 10.0 | 9.9 | 10.0 | 28 Mar 2026 | 19 Aug 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 10.0 | 10.0 | 10.0 | 23 Feb 2026 | 3 Mar 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 10.0 | 10.0 | 10.0 | 13 May 2026 | 23 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 10.0 | 10.0 | 10.0 | 3 Mar 2026 | 18 May 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 10.0 | 10.0 | 10.0 | 11 Jun 2026 | 27 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 10.0 | 10.0 | 10.0 | 2 Dec 2025 | 3 Mar 2026 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 9.9 | 9.9 | 10.0 | 15 Feb 2026 | 8 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 17 Dec 2025 | 24 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 9.9 | 9.9 | 10.0 | 10 Jan 2026 | 3 May 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 9.9 | 9.9 | 10.0 | 9 Jan 2026 | 12 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 3 | 9.9 | 9.9 | 10.0 | 16 Mar 2026 | 11 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 9.9 | 9.9 | 10.0 | 17 Apr 2026 | 26 Jul 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 9.9 | 9.9 | 10.0 | 3 Dec 2025 | 6 Aug 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 2 | 9.9 | 9.9 | 10.0 | 23 Nov 2025 | 24 Apr 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 9.9 | 9.9 | 9.9 | 5 Jul 2026 | 7 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 2 | 9.9 | 9.9 | 10.0 | 14 Feb 2026 | 7 Mar 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 9.9 | 9.9 | 10.0 | 11 Dec 2025 | 20 Apr 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 2 | 9.1 | 8.8 | 9.4 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 4 | 8.9 | 8.4 | 9.2 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 5 | 8.8 | 7.2 | 9.8 | 21 May 2026 | 21 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 5 | 8.8 | 8.3 | 9.1 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 6 | 8.5 | 6.8 | 9.5 | 24 May 2026 | 24 May 2026 |
| Qingdao Saber Technology Pharma QSTCASE #VI-2026-0467 | X | 1 | 8.0 | 8.0 | 8.0 | 27 Feb 2025 | 27 Feb 2025 |
| Shandong Nuoweiou Medical Technology CoCASE #VI-2026-0076 | X | 1 | 8.0 | 8.0 | 8.0 | 13 Jun 2025 | 13 Jun 2025 |
| LiliPeptideCASE #VI-2026-0695 | X | 4 | 7.9 | 6.6 | 9.3 | 25 Apr 2025 | 21 May 2026 |
| TSC Top Supplements ChinaCASE #VI-2026-0523 | X | 5 | 7.4 | 5.4 | 9.3 | 6 May 2025 | 21 May 2026 |
| Nanjing Xiyuxun Technology XYXCASE #VI-2026-0433 | X | 1 | 7.1 | 7.1 | 7.1 | 9 Jun 2025 | 9 Jun 2025 |
| Peptide TechnologiesCASE #VI-2026-0694 | X | 1 | 7.0 | 7.0 | 7.0 | 16 Mar 2025 | 16 Mar 2025 |
| OmegAminoCASE #VI-2026-0014 | X | 1 | 6.9 | 6.9 | 6.9 | 2 Apr 2025 | 2 Apr 2025 |
| Polaris PeptidesCASE #VI-2026-0839 | X | 2 | 6.7 | 6.4 | 7.0 | 21 May 2025 | 20 May 2026 |
| ZLZ PeptideCASE #VI-2026-0524 | X | 10 | 6.6 | 4.2 | 9.7 | 27 Feb 2025 | 21 May 2026 |
| Zhang TYCASE #VI-2026-0070 | X | 1 | 6.6 | 6.6 | 6.6 | 11 Jun 2025 | 11 Jun 2025 |
| Pure RawzCASE #VI-2026-0767 | X | 2 | 6.5 | 5.2 | 7.8 | 2 Apr 2025 | 26 Jan 2026 |
| Tianjin Ruiwang New Material Technology CoCASE #VI-2026-0192 | X | 2 | 6.5 | 6.0 | 6.9 | 8 Jul 2025 | 25 May 2026 |
| NextechLabsCASE #VI-2026-0285 | X | 2 | 6.4 | 5.6 | 7.3 | 24 Apr 2025 | 20 May 2026 |
| Allen Biotechnology Co ABCCASE #VI-2026-0709 | X | 3 | 6.3 | 5.8 | 7.0 | 3 Jun 2025 | 24 May 2026 |
| Richards Biotech Simply RichardsCASE #VI-2026-0307 | X | 1 | 6.1 | 6.1 | 6.1 | 8 Jul 2025 | 8 Jul 2025 |
| Xian Yihang TechnologyCASE #VI-2026-0656 | X | 4 | 5.9 | 4.1 | 7.2 | 13 Jun 2025 | 19 Jan 2026 |
| Limitless Life NootropicsCASE #VI-2026-0980 | X | 2 | 5.6 | 5.2 | 5.9 | 20 Jun 2025 | 19 Jan 2026 |
| Hangzhou Mandy BiotechnologyCASE #VI-2026-0695 | X | 1 | 5.5 | 5.5 | 5.5 | 8 Jul 2025 | 8 Jul 2025 |
| Oasis PeptidesCASE #VI-2026-0404 | X | 1 | 5.3 | 5.3 | 5.3 | 9 Jun 2025 | 9 Jun 2025 |
| Astro PeptidesCASE #VI-2026-0424 | X | 1 | 5.3 | 5.3 | 5.3 | 25 Apr 2025 | 25 Apr 2025 |
| Peptides 4 ResearchCASE #VI-2026-0511 | X | 2 | 5.2 | 4.6 | 5.7 | 14 Jan 2025 | 21 May 2026 |
| PurePeptidesCASE #VI-2026-0234 | X | 1 | 4.0 | 4.0 | 4.0 | 2 Jul 2025 | 2 Jul 2025 |
| Changan District Sheng Peptide TradingCASE #VI-2026-0341 | X | 1 | 3.9 | 3.9 | 3.9 | 13 Feb 2025 | 13 Feb 2025 |
| Peptide ArkCASE #VI-2026-0350 | X | 1 | 1.9 | 1.9 | 1.9 | 20 Jun 2025 | 20 Jun 2025 |
| Hebei Chengtong TechnologyCASE #VI-2026-0520 | X | 1 | 0.3 | 0.3 | 0.3 | 2 Apr 2025 | 2 Apr 2025 |
| Weifang Xingbei International TradeCASE #VI-2026-0766 | X | 1 | 0.0 | 0.0 | 0.0 | 3 Jul 2025 | 3 Jul 2025 |
| Marvel PeptideCASE #VI-2026-0507 | X | 1 | 0.0 | 0.0 | 0.0 | 17 Dec 2024 | 17 Dec 2024 |
Open any subject to view the batch-level evidence for Humanin alone.